"Under the terms of the collaboration, Starpharma will license the IP to Petalion on an exclusive basis for a mutually agreed target."
Rather vague. Is there just one and only one target? Or are there many targets? If there are many targets then exclusivity could scupper most or all of the current potential DEP deals that have been bubbling for years, which could mean that any hope that remains of a megadollar DEP deal in the near future has just flown out of the window.
"If successful, the oncology therapies that Petalion will develop have the potential to become an important treatment modality for a potentially wide range of cancer indications."
Note that "therapies" is plural, and note the "wide range".
SPL Price at posting:
14.5¢ Sentiment: None Disclosure: Not Held
